Acrivon Therapeutics insider transactions
ACRV, SEC Form 4, July 21 to October 22, 2026
- Open-market purchases
- $00 transactions
- Open-market sales
- $41,33510 transactions
- Net
- −$41,335Purchases minus sales
- People
- 711 Form 4 filings
Weekly purchases and sales
Open marketPurchases, none
Sales, highest week $30,969
People
Open-market net, last reported holdingPeter Blume-JensenCEO, last trade Aug 25
−$34,4122,230,052 shares
Mary MillerChief legal officer, last trade Oct 22
−$2,90981,202 shares
Adam D. LevyCFO, last trade Aug 4
−$1,79366,008 shares
Eric DevroeCOO, last trade Aug 18
−$1,214146,349 shares
Erick GamelinOfficer, last trade Aug 18
−$80452,592 shares
Katharine PetersonChief accounting officer, last trade Aug 18
−$20318,033 shares
Michaela LevinOfficer, last trade Aug 31
No purchases or sales30,000 shares
Price and insider transactions
ACRV daily close, Apr 27 to October 26, 2026$2.39$1.38
Daily close
Sale
Purchases and sales
10 transactionsPersonTransactionSharesPriceAmountDate
How to read
Purchases and sales are open-market transactions only (codes P and S). Partial trades in the same filing are combined on one row, and the price is a weighted average.